MedFirst Healthcare Services (4175) reported revenue of NT$697.7 million for Oct 2026, +3.3% year on year and +5.3% from the previous month. Revenue for Jan–Oct 2026 was NT$6.68 billion (+1.5% year on year).
Year-on-year revenue growth: 5 months in a row. →
In Oct 2026, it ranked No. 12 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$697.7 million | +3.3% | +5.3% |
| Sep 2026 | NT$662.6 million | +0.3% | -4.4% |
| Aug 2026 | NT$693 million | +3.7% | +5.2% |
| Jul 2026 | NT$659 million | +0.5% | -15.0% |
| Jun 2026 | NT$775 million | +11.0% | +18.1% |
| May 2026 | NT$656.2 million | -4.9% | +1.8% |
| Apr 2026 | NT$644.4 million | +3.6% | -5.5% |
| Mar 2026 | NT$682.1 million | -0.2% | +21.6% |
| Feb 2026 | NT$560.7 million | -4.9% | -13.0% |
| Jan 2026 | NT$644.5 million | +2.3% | -21.1% |
| Dec 2025 | NT$817.3 million | +1.8% | +31.5% |
| Nov 2025 | NT$621.6 million | +2.7% | -8.0% |
| Oct 2025 | NT$675.5 million | +5.2% | +2.3% |
| Sep 2025 | NT$660.6 million | +1.7% | -1.1% |
| Aug 2025 | NT$668.3 million | +3.0% | +1.9% |
| Jul 2025 | NT$655.8 million | +5.4% | -6.1% |
| Jun 2025 | NT$698.1 million | -2.3% | +1.1% |
| May 2025 | NT$690.3 million | +9.5% | +11.0% |
| Apr 2025 | NT$622.2 million | +4.6% | -9.0% |
| Mar 2025 | NT$683.8 million | +6.5% | +16.0% |
| Feb 2025 | NT$589.7 million | +5.8% | -6.4% |
| Jan 2025 | NT$629.9 million | -1.1% | -21.5% |
| Dec 2024 | NT$802.7 million | +8.4% | +32.6% |
| Nov 2024 | NT$605.4 million | -2.0% | -5.7% |
| Oct 2024 | NT$642 million | -0.1% | -1.2% |
Jan–Oct 2026 cumulative: NT$6.68 billion (+1.5% YoY)
Other Biotech & Medical companies
Compare with peers: MedFirst Healthcare Services vs PEC / MedFirst Healthcare Services vs Lotus Pharm / MedFirst Healthcare Services vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16